We cannot verify your location
Browse Book and Journal Content on Project MUSE
OR

Profits before People?

Ethical Standards and the Marketing of Prescription Drugs

Leonard J. Weber

Publication Year: 2006

The pharmaceutical industry has come under intense criticism in recent years. One poll found that 70% of the sample agreed that drug companies put profits ahead of people. Is this perception accurate? Have drug companies traded ethics for profits and placed people at risk?

In Profits before People? Leonard J. Weber exposes pharmaceutical industry practices that have raised ethical concerns. Providing systematic ethical analysis and reflection, he discusses such practices as compensating physicians for serving as speakers or consultants, providing incentives to physicians to enroll patients as subjects in clinical research, and advertising prescription drugs to the public through the mass media. Weber's critique of the industry is stern. While acknowledging that new industry guidelines are promising, he finds much room for improvement in the way drug companies market their products. Yet Weber makes a strong case that profits and ethics can coexist and that they are not mutually exclusive.

In an effort to understand the proper place of commerce in disseminating information about new drugs, the book aims to clarify basic responsibilities and to help identify sound ethical practices. It recognizes that ethics and law are not the same, that "having a right" is different from "doing the right thing," and that taking ethics seriously means recognizing that the law does not answer all questions about what is right. Weber points the way to more demanding standards and better practices that might begin to restore confidence in the drug industry.

Published by: Indiana University Press

Contents

pdf iconDownload PDF (59.5 KB)
pp. vi-vii

read more

Acknowledgments

pdf iconDownload PDF (50.8 KB)
pp. ix-

I am indebted to many individuals for supporting this project and for assistance in completing the manuscript, including Robert Hall, Carol Bayley, Michael McManus, Jessica Seck, Margaret Weber, and Gloria Albrecht. Thank you. I am particularly grateful to Thomas Schindler for repeated and careful...

read more

Introduction

pdf iconDownload PDF (92.5 KB)
pp. 1-8

“It has all gone terribly wrong for the dozen or so manufacturers that make up ‘big pharma.’” This statement introduced a review of the pharmaceutical industry’s problems in a March 2005 article in The Economist.1 The once well-respected drug companies are now being subjected to fierce criticism...

PART ONE: THE LIMITS OF COMMERCIAL INTERESTS

pdf iconDownload PDF (25.8 KB)
pp. 9-

read more

1. Ethics and For-Profit Business

pdf iconDownload PDF (116.9 KB)
pp. 11-23

Knowing how to relate ethics and the financial bottom line is one of the biggest challenges facing all who seek to manage a business responsibly. Neither ethics education nor business education has, it appears, adequately prepared most people to include dollars comfortably and skillfully in ethical discernment and to...

read more

2. The Pharmaceutical Industry and Its Stakeholders

pdf iconDownload PDF (119.6 KB)
pp. 24-33

One of the most important developments in business ethics in recent years has been recognizing the importance of stakeholder analysis in determining ethical responsibility. “Stakeholders” are identified as those who have something at stake in a company’s “products, operations, markets, industry, and outcomes.”2 They are “persons and groups that stand to benefit from, or be harmed ...

PART TWO: MARKETING TO HEALTHCARE PROFESSIONALS

pdf iconDownload PDF (25.8 KB)
pp. 35-

read more

3. Drug Companies and Healthcare Professionals: The Ethics Agenda

pdf iconDownload PDF (136.2 KB)
pp. 37-52

My experience was probably similar to that of many others. I went with a patient to a doctor’s appointment a couple of years ago. As we sat, I began to pay careful attention to what was taking place in the waiting room. Centered in the room was a television featuring a series of short educational programs on health-related topics. ...

read more

4. Medical Professionalism and Scientific Integrity

pdf iconDownload PDF (116.2 KB)
pp. 53-65

In an essay in The New York Times, Abigail Zuger provided an example of a physician’s prescribing behavior being influenced by exposure to pharmaceutical marketing. She tells the story of a physician friend. He is someone who deplores the extent to which such marketing has affected the prescribing habits of colleagues but...

read more

5. The Industry’s Code: Not Good Enough

pdf iconDownload PDF (139.4 KB)
pp. 66-81

The “PhRMA Code on Interactions with Healthcare Professionals,” published in 2002, is a very significant document. It represents an acknowledgment, on the part of the industry, that laws and governmental regulations are not sufficient to provide full guidance to what is good ethical practice. It is a recognition, in effect, that some of the concerns that have been raised about marketing...

read more

6. Drug Samples: The Most Important Gifts

pdf iconDownload PDF (108.8 KB)
pp. 82-92

Central to the techniques used in marketing pharmaceuticals to healthcare professionals is the practice of providing samples of prescription drugs. Thousands of company sales representatives make frequent visits to physician offices and routinely leave samples of medications. Having them available in their offices, physicians can and do distribute these medications to patients. The practice...

read more

7. Marketing Is Not Objective Education

pdf iconDownload PDF (116.4 KB)
pp. 93-105

Every year, practicing physicians receive a free copy of the Physicians Desk Reference (PDR), the reference that most of them make use of as a source of drug information. “Overall, doctors refer to the PDR 265,000,000 times a year.”2 The information in the PDR is written by drug companies and the companies support...

read more

8. Medical Education: Industry at Arm’s Length

pdf iconDownload PDF (117.6 KB)
pp. 106-118

It is a most interesting arrangement, one that many of the public are unaware of and one that most physicians take for granted: much of the CME that is required for physicians in order to maintain their medical licenses is paid for by pharmaceutical companies. CME is mandated for physicians in order to assure...

read more

9. Clinical Research and the Limits of Commercial Interests

pdf iconDownload PDF (170.8 KB)
pp. 119-139

In an editorial in JAMA, Bruce Psaty and Drummond Rennie considered the ethical legitimacy of the decision on the part of a sponsor to stop a clinical trial before sufficient data were gathered to yield scientifically valid results. The early termination of a comparative investigation of different treatments...

PART THREE: MARKETING TO THE PUBLIC

pdf iconDownload PDF (25.8 KB)
pp. 141-

read more

10. Citizens and Consumers

pdf iconDownload PDF (122.9 KB)
pp. 143-156

Americans widely believe and are frequently told by political leaders that “we’ve got the best health care system in the world.”2 How good a country’s healthcare system is can be determined, in part, by the health of the population. To measure a country’s health, the World Health Organization (WHO) developed an indicator of “healthy life expectancy,” which...

read more

11. Direct-to-Consumer Advertising: Conflicting Interest

pdf iconDownload PDF (117.0 KB)
pp. 157-169

In December, 2004, Pfizer suspended its advertising of the pain reliever Celebrex on radio, on TV, in newspapers, and in magazines. This decision, made in conversations with the FDA, followed the release of study results which suggested an increased risk of heart attacks in patients who took high dosages of Celebrex. Pfizer’s decision on DTC advertising...

read more

12. Direct-to-Consumer Advertising: Better Is Better

pdf iconDownload PDF (112.9 KB)
pp. 170-181

In October 2004, the Prescription Access Litigation Project (PAL) filed a lawsuit under California’s Unfair Competition and False Advertising Laws against AstraZeneca. AstraZeneca makes and markets Nexium, a proton pump inhibitor used in the treatment of gastroesophageal reflux disease (GERD), often called acid reflux. PAL litigates against what it...

read more

Conclusion

pdf iconDownload PDF (71.1 KB)
pp. 182-184

Pharmaceutical industry leaders often emphasize their investment in research and development and describe their enterprise as research-based or research-driven. Critics, on the other hand, point to the large expenditures drug companies make in marketing their medications and refer to the industry as marketing-driven. I have ...

Notes

pdf iconDownload PDF (113.7 KB)
pp. 185-197

Index

pdf iconDownload PDF (107.9 KB)
pp. 199-206


E-ISBN-13: 9780253112101
E-ISBN-10: 0253112109
Print-ISBN-13: 9780253347480

Page Count: 224
Publication Year: 2006

Series Title: Bioethics and the Humanities